The superoxide production mediated by the redox cycling of xenobiotics in rat brain microsomes is dependent on their reduction potential

Brain Research

Volumn 725, Issue 2, 1996, Pages 207-216

  Livertoux, Marie Helène ^a   Lagrange, Philippe ^a   Minn, Alain ^a  

^a Centre du Medicament URA CNRS 597   (France)

Author keywords

Bipyridinium; Brain ageing; Electron affinity; NADPH cytochrome P 450 reductase; Neurodegeneration; Nitroheterocycle; Quinone; Rat brain microsomes; Redox cycling of xenobiotics; Reduction potential; Superoxide radical

Indexed keywords

1,3 DINITROBENZENE; 1,4 BENZOQUINONE; 1,4 NAPHTHOQUINONE 2 SULFONIC ACID; 2,5 DIMETHYLBENZOQUINONE; ANTHRAQUINONE 2 SULFONATE; BENZYLVIOLOGEN; CYTOCHROME C; DIQUAT; DUROQUINONE; FLAVOPROTEIN; FLUNITRAZEPAM; INDIGO CARMINE; MENADIONE; METHYLBENZOQUINONE; METRONIDAZOLE; MITOMYCIN C; N,N DIMETHYLFORMAMIDE; NIMETAZEPAM; NIRIDAZOLE; NITRAZEPAM; NITRO DERIVATIVE; NITROBENZOIC ACID DERIVATIVE; NITROFURAL; PARAQUAT; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SUPEROXIDE; UNCLASSIFIED DRUG; VIOLOGEN; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MICROSOME; ELECTRON TRANSPORT; MALE; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; XENOBIOTIC METABOLISM;

EID: 0030182342     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00251-X     Document Type: Article

References (53)

1. [1] Adams, J.D., Jr. and Odunze, I.N., Oxygen free radicals and Parkinson's disease, Free Rad. Biol. Med., 10 (1991) 161-169.
2. [2] Ames, J.R., Brandänge, S., Rodriguez, B., Castagnoli, N., Ryan, M.D. and Kovacic, P.. Cyclic voltammetry with cyclic iminium ions: implications for charge transfer with biomolecules (metabolites of nicotine, phencyclidine, and spermine), Bioorg. Chem., 14 (1986) 228-241.
3. [3] Azzi, A., Montecucco, C. and Richter, C., The use of acetylated ferricytochrome c for the detection of superoxide radicals produced in biological membranes, Biochem. Biophys. Res. Commun., 65 (1975) 597-607.
4. [4] Bachur, N.R., Gordon, S.L. and Gee, M.V., A general mechanism for microsomal activation of quinone anticancer agents to free radicals, Cancer Res., 38 (1978) 1745-1750.
5. [5] Black, S. and Coon, M.J., Structural features of liver microsomal NADPH-cytochrome P450 oxidoreductase: hydrophobic domain, hydrophilic domain, and connecting region, J. Biol. Chem., 257 (1982) 5929-5938.
6. [6] Butler, J. and Hoey, B.M., The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase, Biochim. Biophys. Acta, 1161 (1993) 73-78.
7. [7] Calne, D.B., Duvoisin, R.C. and McGeer, E., Speculations on the etiology of Parkinson's disease, Ann. Neurol., 40 (1984) 353-360.
8. [8] Cénas, N., Anusevicius, Z., Bironaité, D., Bachmanova, G.I., Archakov, A.I. and Öllinger, K., The electron transfer reactions of NADPH:cytochrome P450 reductase with nonphysiological oxidants, Arch. Biochem. Biophys., 315 (1994) 400-406.
9. [9] Cohen, G., Oxy-radical toxicity in catecholamine neurons, Neurotoxicology, 5 (1984) 77-82.
10. [10] Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. and Marsden, C.D., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease, J. Neurochem. 52 (1989) 381-389.
11. [11] Donaldson, J., The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders, Neurotoxicology, 8 (1987) 451-462.
12. [12] Gee, P. and Davison, A.J., Intermediates in the aerobic autooxidation of 6-hydroxydopamine: relative importance under different reaction conditions, Free Rad. Biol. Med., 6 (1989) 271-284.
13. [13] Gershanik, O.S., Drug induced parkinsonism in the aged. Recognition and prevention, Drugs Aging, 5 (1994) 127-132.
14. [14] Ghersi-Egea, J.F., Minn, A., Daval, J.L., Jayyosi, Z., Arnould. V., Souhaili-El Amri, H. and Siest, G., NADPH-cytochrome P450(c) reductase: biochemical characterization in rat brain and cultured neurones and evolution of activity during development. Neurochem. Res., 14 (1989) 883-888.
15. [15] Ghersi-Egea, J.F., Livertoux, M.H., Minn, A., Perrin, R. and Siest, G., Enzyme mediated superoxide radical formation initiated by exogenous molecules in rat brain preparations, Toxicol. Appl. Pharmacol., 110 (1991) 107-117.
16. [16] Harman, D.. Free radicals and aging, Mol. Cell. Biochem., 84 (1988) 155-161.
17. [17] Iyanagi, T., On the mechanisms of one-and two-electron transfer by flavin enzymes, Chem. Scripta, 27(A) (1987) 31-36.
18. [18] Iyanagi, T., Makino, N. and Mason, H.S., Redox properties of the reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 and reduced nicotinamide adenine dinucleotide-cytochrome b5 reductases, Biochemistry, 13 (1974) 1701-1710.
19. [19] Jeding, I., Evans, P.J., Akanmu, D., Dexter, D.. Spencer, J.D., Aruoma, O.I., Jenner, P. and Halliwell, B., Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs, Biochem. Pharmacol., 49 (1995) 359-365.
20. [20] Jenner, P., Oxidative damage in neurodegenerative disease, Lancet. 344 (1994) 796-798.
21. [21] Klopman, G. and Doddapaneni, N., Electrochemical behavior of substituted polycyclic aromatic quinones, J. Phys. Chem., 78 (1974) 1820-1825.
22. [22] Kovacic, P., Ames, J.R. and Ryan, M.D., Reduction potentials of antimycobacterial agents; relationship to activity, Bioelectrochem. Bioenerg., 21 (1989) 269-278.
23. [23] Lagrange, P., Livertoux, M.H., Grassiot, M.C. and Minn, A., Superoxide anion production during monoelectronic reduction of xenobiotics by subcellular fractions. Free Rad. Biol. Med., 17 (1994) 355-359.
24. [24] Lagrange, P., Livertoux, M.H., Chat, M. and Minn, A., Inhibition of rat brain microsomal cytochromes P450 1A and 2B activities by superoxide radicals. Submitted.
25. [25] Le Bel, B.E. and Bondy, S.C., Oxidative damage and cerebral aging. Prog. Neurobiol., 38 (1992) 601-609.
26. [26] Lees, G.J., Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience, 54 (1993) 287-322.
27. [27] Leibowitz, B.E. and Siegel, B.V., Aspects of free radical reactions in biological systems: aging, J. Gerontol., 35 (1980) 45-56.
28. [28] Lowry, O.H., Rosenbrough, N.J., Fair, A.L. and Randall, R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
29. [29] Magdalou, J., Thirion, C., Balland, M. and Siest, G., Conformation studies of NADPH cytochrome P450 reductase by circular dichroism interaction with phospholipids, Int. J. Biochem., 17 (1985) 1103-1107.
30. [30] Maret, G., Tayar, N.E., Carrupt, P.A., Testa, B., Jenner, P. and Baird, M., Toxication of MPTP (1-methyl-1,2,3,6-tetrahydropyridine), Biochem. Pharmacol., 40 (1990) 783-792.
31. 2 inhibition of nitroreductase, Biochem. Biophys. Res. Commun., 67 (1975) 1267-1274.
32. [32] Mikani, S., Ringler, R.L. and Singer, T.P., Studies of the respiratory-chain-linked dihydrophosphopyridine nucleotide deshydrogenase, J. Biol. Chem., 237 (1976) 569-576.
33. [33] Olesen, S.P., Free radicals decrease electrical resistance of microvascular endothelium in brain, Acta Physiol. Scand., 129 (1987) 181-187.
34. [34] Olive, P.L., Correlation between metabolic reduction rates and electron affinity of nitroheterocycles, Cancer Res., 39 (1979) 4512-4515.
35. [35] Olive, P.L., Inhibition of DNA synthesis by nitroheterocycles. 1. Correlation with half-wave reduction potential, Br. J. Cancer, 40 (1979) 89-94.
36. [36] Olive, P.L. and Durand, R.E., Activation of radiosensitizers by hypoxic cells, Br. J. Cancer, 37 (1978) 124-127.
37. [37] Powis, G. and Appel, P.L., Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins, Biochem. Pharmacol., 29 (1980) 2567-2572.
38. [38] Powis, G., Svingen, B.A. and Appel, P., Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells, Mol. Pharmacol., 20 (1981) 387-394.
39. [39] Powis, G., Free radical formation by antitumor quinones, Free Rad. Biol. Med., 6 (1989) 63-101.
40. [40] Richardson, J.S., Free radicals in the genesis of Alzheimer's disease, Ann. NY Acad. Sci., 695 (1993) 73-76.
41. [41] Sato, K., Akaike, T., Suga, M., Ando, M. and Merada, H., Generation of free radical from neocarsinostatin mediated by NADPH/cytochrome P-450 reductase via activation of enediyne chromophore, Biochem. Biophys. Res. Commun., 205 (1994) 1716-1723.
42. [42] Schapira, A.H.V.. Oxidative stress in Parkinson's disease - review, Neuropathol. Appl. Neurobiol., 21 (1995) 3-9.
43. [43] Smith, M.A., Sayre, L.M., Monnier, V.M. and Perry, G., Radical ageing in Alzheimer's disease, Trends Neurosci., 18 (1995) 172-176.
44. [44] Strobel, H.W. and Digman, J.D., Purification and properties of NADPH cytochrome P-450 reductase, Methods Enzymol., 52 (1978) 89-96.
45. [45] Svingen, B.A. and Powis, G., Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen and one-electron reduction potentials, Arch. Biochem. Biophys., 209 (1981) 119-126.
46. [46] Swallow, A.J., In B.L. Trumpower (Ed.), Functions of Quinones in Energy Conversing Systems, Academic Press, London, 1982, pp. 59-72.
47. [47] Tew, D.G., Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications, Biochemistry, 32 (1993) 10209-10215.
48. [48] Vermilion, J.L., Ballou, D.P., Massey, V. and Coon, M.J., Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase, J. Biol. Chem., 256 (1981) 266-277.
49. [49] Volicer, L. and Crino, P.B., Involvement of free radicals in dementia of the Alzheimer type: a hypothesis, Neurobiol. Aging, 11 (1990) 567-571.
50. [50] Wardman, P. and Clarke, E.D., Oxygen inhibition of nitroreductase: electron transfer from nitro radical-anions to oxygen, Biochem. Biophys. Res. Commun., 69 (1976) 942-949.
51. [51] Wardman, P., Reduction potentials of one-electron couples involving free radicals in aqueous solution, J. Phys. Chem. Ref. Data, 18 (1989) 1637-1755.
52. + toxicity?, Proc. West. Pharmacol. Soc., 32 (1989) 191-193.
53. [53] Youdim, M.B.H., Ben-Shachar, D. and Riederer, P., Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?, Acta Neurol. Scand., 126 (1989) 47-54.